|
|
Post by Clement on Jan 29, 2024 8:33:06 GMT -5
Analysts Are Optimistic We'll See A Profit From MannKind Corporation (NASDAQ:MNKD) finance.yahoo.com/news/analysts-optimistic-well-see-profit-103830020.html"MannKind is bordering on breakeven, according to the 6 American Biotechs analysts. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$32m in 2024. Therefore, the company is expected to breakeven roughly a year from now or less!" |
|
|
|
Post by boca1girl on Jan 30, 2024 11:08:27 GMT -5
The article doesn’t really say anything but getting attention with the article can’t hurt.
|
|
|
|
Post by cretin11 on Jan 30, 2024 17:17:53 GMT -5
The article doesn’t really say anything but getting attention with the article can’t hurt. Agree boca, we'll take any positive attention, even if a bot wrote it. Funny how it says excitedly "the company is expected to breakeven roughly a year from now or less!" I thought we already celebrated breakeven? Hopefully the next time we get to celebrate that milestone, our share price will actually appreciate rather than depreciate. "Breakeven: Take 2!" |
|
|
|
Post by prcgorman2 on Jan 31, 2024 7:18:18 GMT -5
Bot or not, it beats hit pieces.
|
|
|
|
Post by ktim on Jan 31, 2024 12:33:25 GMT -5
Analysts Are Optimistic We'll See A Profit From MannKind Corporation (NASDAQ:MNKD) finance.yahoo.com/news/analysts-optimistic-well-see-profit-103830020.html"MannKind is bordering on breakeven, according to the 6 American Biotechs analysts. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$32m in 2024. Therefore, the company is expected to breakeven roughly a year from now or less!" Breaking even roughly a year from now and making $32M in profit in 2024? Sounds like they're predicting that rocket ship takeoff late in the year that was always discussed here, lol... or that's an article written by neural network. |
|
|
|
Post by prcgorman2 on Jan 31, 2024 12:55:03 GMT -5
I agree with cretin11 it’s a bot-built banal blast and I ignore everything it has to say but am pleased it is a positive spin instead of the more usual negative spin. I do think ~$32M in profit in 2024 is possible, but I’m guessing MannKind would prefer to pile that profit into eliminating the MidCap and Mann Group debt sooner rather than later. That’s what CFO Binder indicated was their intention during the short announcement on the Sagard cash raise, so I assume they’ll do what they said they planned.
|
|
|
|
Post by awesomo on Jan 31, 2024 13:17:21 GMT -5
Binder already said the next "few quarters" will be flat profit wise. That pretty takes +$32M profit for 2024 off the table.
|
|
|
|
Post by ktim on Jan 31, 2024 13:22:17 GMT -5
I agree with cretin11 it’s a bot-built banal blast and I ignore everything it has to say but am pleased it is a positive spin instead of the more usual negative spin. I do think ~$32M in profit in 2024 is possible, but I’m guessing MannKind would prefer to pile that profit into eliminating the MidCap and Mann Group debt sooner rather than later. That’s what CFO Binder indicated was their intention during the short announcement on the Sagard cash raise, so I assume they’ll do what they said they planned. It sounds like management would prefer putting the revenue into the pipeline (given statements about hovering around breakeven for coming quarters). Paying off debt would not reduce profit. That would just appear in cash flow statement, not earnings. In any case, doesn't sound like management is expecting $32M in profit this year. It might be possible if that were the goal of management... though almost entirely dependent on UTHR's execution and what happens with LQDA. |
|
|
|
Post by sayhey24 on Jan 31, 2024 16:29:54 GMT -5
Binder already said the next "few quarters" will be flat profit wise. That pretty takes +$32M profit for 2024 off the table. Lets hope so and we put more money into more trials. |
|
|
|
Post by prcgorman2 on Jan 31, 2024 17:44:19 GMT -5
I agree with cretin11 it’s a bot-built banal blast and I ignore everything it has to say but am pleased it is a positive spin instead of the more usual negative spin. I do think ~$32M in profit in 2024 is possible, but I’m guessing MannKind would prefer to pile that profit into eliminating the MidCap and Mann Group debt sooner rather than later. That’s what CFO Binder indicated was their intention during the short announcement on the Sagard cash raise, so I assume they’ll do what they said they planned. It sounds like management would prefer putting the revenue into the pipeline (given statements about hovering around breakeven for coming quarters). Paying off debt would not reduce profit. That would just appear in cash flow statement, not earnings. In any case, doesn't sound like management is expecting $32M in profit this year. It might be possible if that were the goal of management... though almost entirely dependent on UTHR's execution and what happens with LQDA. I think you and awesomo are both correct. I think you know income statement and balance sheet accounting and reporting better than I do. I knew it well when I was studying and taking tests, but not anymore and I don't try to pour over those documents (obviously).
I was thinking about the additional cash available from increased interest income, decreased expenses (from the renegotiated Amphastar insulin agreement if nothing else) and presumed increases in royalty payments (notwithstanding the 1% of the 10% that will be paid to Sagard for the cash that is earning additional interest income). Also Binder said they were going to be paying off the MidCap and Mann Group debt and at nearly the same time he said EPS will be hovering around $0 for some indeterminate number of quarters.
So there is another possibility that in addition to increasing spend on pipeline that they could be banking the additional income in order to be able to pay off the convertible debt entirely with cash. I would be surprised if that was the plan, but there is a gap between what they acquired from the Sagard agreement and the amount of convertible debt coming due so it is a possibility.
|
|
|
|
Post by Chris-C on Feb 1, 2024 10:26:27 GMT -5
Let's hope for great execution by UTHR before LQDA comes online in March. UTHR's head start should be a useful advantage. I fully support the strategy of MNKD paying down the restrictive debt and moving the pipeline ahead. We longs have been waiting over 10 years, so another year to profitability doesn't seem like a big deal to me.
|
|
|
|
Post by agedhippie on Feb 1, 2024 17:19:15 GMT -5
Let's hope for great execution by UTHR before LQDA comes online in March. UTHR's head start should be a useful advantage. I fully support the strategy of MNKD paying down the restrictive debt and moving the pipeline ahead. We longs have been waiting over 10 years, so another year to profitability doesn't seem like a big deal to me. I don't think LQDA will launch properly until May at the earliest. The PH-ILD exclusivity lasts until the end of March and LQDA are going to want to launch with both indications on their label. My feeling is that the FDA will delay approval until after that expires. |
|
|
|
Post by Chris-C on Feb 2, 2024 16:25:30 GMT -5
Let's hope for great execution by UTHR before LQDA comes online in March. UTHR's head start should be a useful advantage. I fully support the strategy of MNKD paying down the restrictive debt and moving the pipeline ahead. We longs have been waiting over 10 years, so another year to profitability doesn't seem like a big deal to me. I don't think LQDA will launch properly until May at the earliest. The PH-ILD exclusivity lasts until the end of March and LQDA are going to want to launch with both indications on their label. My feeling is that the FDA will delay approval until after that expires. Agedhippie: I hope you are correct on all points. Even better to allow UTHR to get some additional traction for their product in the market. I'm eagerly awaiting the coming quarterly reports for both UTHR and MNKD to get a sense of how things are going. Somehow, I allowed myself to expect more than delivered at the last report. I hope the projections discussed here begin to show signs of realization. I'm assuming that MNKD would not have been able to do the percentage of royalty deal with Sagard unless there were some pretty compelling projections based on solid data. (Fingers and toes crossed.) |
|
|
|
Post by hellodolly on Feb 3, 2024 8:49:34 GMT -5
I don't think LQDA will launch properly until May at the earliest. The PH-ILD exclusivity lasts until the end of March and LQDA are going to want to launch with both indications on their label. My feeling is that the FDA will delay approval until after that expires. Agedhippie: I hope you are correct on all points. Even better to allow UTHR to get some additional traction for their product in the market. I'm eagerly awaiting the coming quarterly reports for both UTHR and MNKD to get a sense of how things are going. Somehow, I allowed myself to expect more than delivered at the last report. I hope the projections discussed here begin to show signs of realization. I'm assuming that MNKD would not have been able to do the percentage of royalty deal with Sagard unless there were some pretty compelling projections based on solid data. (Fingers and toes crossed.) I agree with you CC. MNKD and Sagard surely each did their own DD based on opportunities and threats i.e.; TAMS, LQDA market share, future earnings, etc. and came to some compelling data to make this deal a win-win. |
|
